NewsBenzingauniQure宣布其用于治疗亨廷顿病的ifezuntirgene inilparvovec正在进行中的I/II期研究公布更多数据；在12名高剂量患者中，48个月时cUHDRS和TFC均持续显示疾病进展显著减缓，并呈现明确的剂量依赖性反应；cUHDRS主要终点显示疾病进展减缓44% uniQure宣布其用于治疗亨廷顿病的ifezuntirgene inilparvovec正在进行中的I/II期研究公布更多数据；在12名高剂量患者中，48个月时cUHDRS和TFC均持续显示疾病进展显著减缓，并呈现明确的剂量依赖性反应；cUHDRS主要终点显示疾病进展减缓44% Benzinga 2026.09.29 11:16 (GMT+0) Open on Benzinga Other news Here's How Much $1000 Invested In Coeur Mining 5 Years Ago Would Be Worth Today Anthropic Gives 5% of Itself to the Public. Musk Answers by Giving Away SpaceX Shares Standex International Appoints Samantha L. Stoddard As CFO Effective December 1, 2026 U.S. Transportation Secretary Duffy Expected To Announce Certification Of Boeing 737 Max 10 On Tuesday In Washington State Vivos Therapeutics Closes Its Acquisition Of An 11% Fully Diluted Equity Interest In Sod Sciences And A 50% Undivided Co-Ownership Interest In SOD's Pseudohypoxia Early‑Warning Test, The "Primed Cell For Chronic Disease" Test; Vivos Issued To SOD 12,000... 12 Industrials Stocks Moving In Monday's After-Market Session
U.S. Transportation Secretary Duffy Expected To Announce Certification Of Boeing 737 Max 10 On Tuesday In Washington State
Vivos Therapeutics Closes Its Acquisition Of An 11% Fully Diluted Equity Interest In Sod Sciences And A 50% Undivided Co-Ownership Interest In SOD's Pseudohypoxia Early‑Warning Test, The "Primed Cell For Chronic Disease" Test; Vivos Issued To SOD 12,000...
